53 studies found for:    "Multiple Sclerosis, Chronic Progressive"
Show Display Options
Rank Status Study
1 Active, not recruiting Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: lipoic acid;   Drug: Placebo
2 Completed Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Cyclophosphamide (drug);   Drug: Methylprednisolone (drug)
3 Unknown  Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: RTL1000 (recombinant T cell receptor ligand);   Drug: RTL1000 Placebo
4 Active, not recruiting China Betaferon Adherence, Coping and Nurse Support Study
Condition: Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
5 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
6 Completed Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Biological: MIS416
7 Active, not recruiting Sunphenon in Progressive Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Sunphenon EGCG;   Drug: Placebo
8 Recruiting Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Biological: MIS416;   Drug: Saline
9 Unknown  Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis
Conditions: Autoimmune Diseases;   Immune System Diseases;   Demyelinating Diseases;   Nervous System Diseases;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System
Intervention: Other: Autologous mesenchymal stem cells from adipose tissue.
10 Recruiting Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study
Condition: Primary Progressive Multiple Sclerosis
Intervention: Other: generation of 'omic markers of disease progression
11 Completed Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Multiple Sclerosis
Intervention: Drug: masitinib
12 Recruiting A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Conditions: Multiple Sclerosis, Remittent Progressive;   Multiple Sclerosis, Primary Progressive;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: fampridine (BIIB041)
13 Terminated Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Secondary Progressive
Intervention: Drug: MBP8298
14 Recruiting A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Relapse Free
Interventions: Drug: masitinib;   Drug: placebo
15 Active, not recruiting Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention:
16 Terminated Study to Compare Double-Dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
17 Recruiting A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Interventions: Drug: Fampridine;   Drug: Placebo
18 Completed Natalizumab Treatment of Progressive Multiple Sclerosis
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Natalizumab
19 Recruiting Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Condition: Multiple Sclerosis
Intervention: Drug: Rituximab
20 Active, not recruiting Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Multiple Sclerosis
Interventions: Other: Progressive exercise;   Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV;   Other: Modified paleolithic diet;   Dietary Supplement: Omega 3 fatty acids;   Dietary Supplement: Full Spectrum vitamin;   Dietary Supplement: Essential - hydroxytyrosol;   Dietary Supplement: Maltodextrin fiber supplement;   Dietary Supplement: Mineral boost (magnesium);   Dietary Supplement: Niacinamide;   Dietary Supplement: Methyl B12;   Dietary Supplement: Taurine;   Dietary Supplement: creatine;   Dietary Supplement: thiamine;   Dietary Supplement: riboflavin;   Dietary Supplement: N acetylcysteine;   Dietary Supplement: alpha lipoic acid;   Dietary Supplement: L acetyl carnitine;   Dietary Supplement: methyl folate;   Dietary Supplement: coenzyme Q;   Behavioral: meditation;   Behavioral: self massage;   Behavioral: learning;   Dietary Supplement: Coconut oil

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years